A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma

  • STATUS
    Recruiting
  • End date
    Sep 1, 2030
  • participants needed
    25
  • sponsor
    David Avigan
Send
Updated on 11 August 2026
See if I qualify

Summary

This research is being done to determine if the combination of the Dendritic Cell (DC)/ Multiple Myeloma (MM) fusion vaccine with elranatamab is safe and effective in treating Relapsed or Refractory Multiple Myeloma (MM).

The names of the study drugs and vaccine involved in this study are:

  • DC/MM fusion vaccine (a personalized cancer vaccine in which harvested participant tumor cells are fused with harvested participant dendritic blood cells)
  • Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) (a type of growth factor)
  • Elranatamab (a type of T-cell engager antibody)

Description

This is a phase 1 study to evaluate the feasibility, safety, clinical and immune effects of DC/MM fusion vaccine in combination with Elranatamab in participants with relapsed/refractory multiple myeloma. The DC/MM fusion vaccine is an investigational agent that tries to help the immune system to recognize and fight against cancer cells. This vaccine is individualized for each participant using dendritic cells (type of immune cells) from each participant. GM-CSF contains a substance that helps make more white blood cells. This medication is being used to possibly increase the effectiveness of the DC/MM fusion vaccine.

The U.S. Food and Drug Administration (FDA) has not approved DC/MM fusion vaccine as a treatment for Relapsed or Refractory Multiple Myeloma.

The FDA has not approved GM-CSF as a treatment for Relapsed or Refractory Multiple Myeloma.

The FDA has approved elranatamab as a treatment option for Relapsed or Refractory Multiple Myeloma.

The research study procedures include screening for eligibility, in-clinic visits, blood tests, urine tests, study drug subcutaneous (under the skin) injections, Computerized Tomography (CT) scans, Magnetic Resonance Imaging (MRI) scans, or Positron Emission (PET) scans, and bone marrow biopsies and aspirations (or collections).

Participants will receive study treatment for up to 12 cycles (28-day cycles) and will be followed for up to 5 years.

It is expected that about 25 people will take part in this research study.

Pfizer is funding this research study by providing one of the study drugs, Elranatamab.

Details
Condition Multiple Myeloma, Relapse Multiple Myeloma, Refractory Multiple Myeloma
Clinical Study IdentifierNCT06799026
SponsorDavid Avigan
Last Modified on11 August 2026

Eligibility

 Yes No Not Sure

Inclusion Criteria

Participants must have an established diagnosis of multiple myeloma
Participant must have multiple myeloma and have relapsed following or are refractory to proteasome inhibitors, IMiDs and anti-CD38 mAb therapy
Participants must have at least 3 prior lines of therapy
Participants must be ≥18 years of age
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
Participants must have > 20% plasma cells in the bone marrow core or aspirate differential <30 days prior to enrollment
ANC > 1K/uL; Platelets > 50 K/uL without transfusional support
Participants must have adequate organ function as defined below
Total bilirubin ≤1.5 x institutional upper limit of normal
AST ≤ 3 x institutional upper limit of normal
ALT ≤ 3 x institutional upper limit of normal
Creatinine clearance ≥ 40 mL/min for participants with creatinine levels above institutional normal
The effects of DC/MM fusion vaccine on the developing human fetus are unknown. For this reason, women and men of child-bearing potential must agree to use adequate contraception (hormonal or barrier methods of birth control or abstinence) prior to study enrollment and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner are participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of treatment
Ability to understand and willingness to sign a written informed consent document

Exclusion Criteria

Patients who are receiving any other investigational agents
Patients with purely non-secretory MM [absence of a monoclonal protein (M protein) in serum as measured by electrophoresis and immunofixation and the absence of Bence- Jones protein in the urine defined by use of conventional electrophoresis and immunofixation techniques and the absence of involved serum free light chain >100 mg/L]. Patients with light chain MM detected in the serum by free light chain assay are eligible
Patients with Plasma Cell Leukemia
Because of compromised cellular immunity, patients who have a known human immunodeficiency virus (HIV), active hepatitis C virus (HCV) or active hepatitis B virus (HBV)
Myocardial infarction within 6 months prior to enrollment or New York Heart Association (NYHA) Class III or IV heart failure (see Appendix H), uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any ECG abnormality at screening will be documented by the investigator as not medically relevant
Active and clinically significant autoimmune or inflammatory disorder requiring active treatment
Individuals with a history of a different malignancy are ineligible except for the following circumstances. Note: Individuals with a history of other malignancies are eligible if they have been disease-free for at least 2 years and are deemed by the investigator to be at low risk for recurrence of that malignancy. Individuals with the following cancers are eligible if diagnosed and treated within the past 5 years: non- invasive cancer (such as, any in situ cancers) and basal cell or squamous cell carcinoma of the skin
Female patients who are pregnant (positive β-HCG) or breastfeeding
Prior organ transplant requiring immunosuppressive therapy
Patients who previously received PD-1 antibody and have experienced toxicities resulting in treatment discontinuation
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
History of GBS or GBS variants, or history of any Grade ≥3 peripheral motor polyneuropathy
Eligibility Criteria Prior to Vaccination with DC/MM fusions
Resolution of all elranatamab related ≥ grade 3 or higher toxicities to grade 1 or baseline. Isolated laboratory abnormalities that are not considered to be clinically significant are not exclusionary
Successful production of at least 2 vaccines with a minimum of 1 x 106 fusion cells per vaccine
Absence of disease progression following 2 cycles of elranatamab therapy
ECOG performance status ≤ 2
Participants must have adequate organ function as defined below
Total bilirubin ≤ 1.5 x institutional upper limit of normal
AST ≤ 3 x institutional upper limit of normal
ALT ≤ 3 x institutional upper limit of normal
ANC > 1K/uL; Platelets > 50 K/uL without transfusional support
Creatinine clearance ≥ 40 mL/min for participants with creatinine levels above institutional normal
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.